Analysis
Tirzepatide and sleep apnea: the Zepbound OSA indication
Zepbound (tirzepatide) was approved for moderate-to-severe obstructive sleep apnea in adults with obesity — a distinct indication beyond weight manage
Zepbound (tirzepatide) was approved for moderate-to-severe obstructive sleep apnea in adults with obesity — a distinct indication beyond weight management. It reflects tirzepatide's effect on weight and, through it, on sleep-disordered breathing. This applies to the approved product, not compounded microdoses.
The full picture
Obstructive sleep apnea is strongly linked to obesity, so a drug that drives substantial weight loss can improve it. Tirzepatide's OSA approval formalized that: it's now indicated for a condition, not just a number on a scale, which broadens who a clinician might consider it for.
Semaglutide doesn't carry this specific OSA indication, which is one of the concrete differences between the two molecules — alongside semaglutide's cardiovascular and adolescent indications running the other way.
As always, the indication belongs to the approved product at studied doses. A compounded tirzepatide microdose has no OSA evidence, and no compounded product is FDA approved for anything.
| Trial | Design | N | Result | Source | ID |
|---|---|---|---|---|---|
| SURMOUNT-1 | RCT, 72 weeks, placebo-controlled | 2,539 | Up to about -20.9% at 15 mg vs -3.1% placebo | N Engl J Med 2022 | NCT04184622 · PMID 35658024 · DOI |
Machine-readable: studies.json.
Frequently asked questions
Is tirzepatide approved for sleep apnea?
Yes — Zepbound is approved for moderate-to-severe OSA in adults with obesity.
Does semaglutide have a sleep-apnea indication?
Not the same one; this is specific to tirzepatide.
Related: evidence database · cost calculator · semaglutide · tirzepatide.
Not medical advice. This page is consumer education, not medical advice, and does not recommend a dose, product, or provider. Compounded medications are not FDA approved. Talk with a licensed clinician about your situation.